BioMarin will discontinue dosing and enrollment of its phase 2 trials for Voxzogo—currently approved in achondroplasia, a ...
It was only nine months ago that Idorsia announced a CEO change, tapping Srishti Gupt | Idorsia is gearing up for another CEO ...
Eli Lilly scored $408 million in U.S. sales of eczema treatment Ebglyss in its first full year on the market in 2025. | With ...
With a fresh phase 3 win for Kerendia, Bayer is one step closer to pushing the ascendant drug into a much broader population ...
The White House’s direct-to-consumer (DTC) platform, TrumpRx, is steadily expanding its catalogue, with products from GSK and Amgen the latest to join the collection of drugs offered through the pr | ...
Johnson & Johnson is suing a former oncology medical affairs employee, alleging a massive and “malicious” stealing of trade secrets. | Johnson & Johnson is suing a former oncology medical affairs ...
Simtra BioPharma Solutions was issued a warning letter by the FDA after an inspection uncovered a number of problems at the ...
From its 17-year development cycle through to its commercial launch, production has always been in Yeztugo’s DNA. | From its ...
Though it’s hard to say exactly what the future holds for mass GLP-1 compounding, the pressure is mounting from multiple angles in the U.S. | Eli Lilly—which has already staged multiple efforts in ...
Veeva is paying approximately $100 million to acquire Ostro, according to this week’s announcement, comprising a combination ...
About five months after U.S. Department of Health and Human Services Secretary Robert F. Kennedy Jr. | About five months after U.S. Health Secretary Robert F. Kennedy Jr. touted leucovorin as “an ...
In this week’s episode of “The Top Line,” we take a deep dive into the fourth-quarter performance of the biopharma industry ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results